A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-19 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Chitosan is produced commercially by deacetylation of chitin, which is the structural element in the exoskeleton of crustaceans (such as crabs and shrimp) and cell walls of fungi. A common method for obtaining chitosan is the deacetylation of chitin using sodium hydroxide in excess as a reagent and water as a solvent. The reaction follows first-order kinetics though it occurs in two steps; the activation energy barrier for the first stage is estimated at 48.8 kJ·mol−1 at 25–120 °C (77–248 °F) and is higher than the barrier to the second stage.
=== Artificial retina === The artificial retina of Professor José Sahel and his team at the Quinze-Vingts National Ophthalmology Hospital Centre aims to allow people with degenerative retinal disease, numbering 1.5 million in 2008, to accomplish everyday activities. Placed under the existing retina, it directly stimulates the neurons, replacing defective cells. These implants should eventually allow patients to recognize faces, read large print and move independently in a restricted environment. The challenge for the Altran teams was to find solutions to produce artificial retina in series, in order to bring solutions to the widest number of patients.
=== For vaccine creation === SeV has several features that are important in a vector for a successful vaccine: the virus does not integrate into the host genome, it does not undergo genetic recombination, it replicates only in the cytoplasm without DNA intermediates or a nuclear phase. SeV, as all other representatives of family Paramyxoviridae, is genetically stable and evolves very slowly. SeV genome can accommodate foreign genes in multiple intergenic positions and the SeV genome is suitable for introducing genes encoding the envelope glycoproteins of pathogenic viruses. For vaccination purpose the virus-based constructs could be delivered in a form of nasal drops, which may be beneficial in inducing a mucosal immune response. This form of vaccination is more immunogenic than intramuscular considering pre-existing anti-SeV antibodies. Sendai virus-based constructs can induce durable, mucosal, B-cell, and T-cell immune responses. The virus genome has high similarity with human parainfluenza virus 1 (HPIV-1) and the two viruses share common antigenic determinants. The study that was published in 2011 demonstrated that SeV neutralizing antibodies (which were formed due to human parainfluenza virus type 1 past infection) can be detected in 92.5% of human subjects worldwide with a median EC50 titer of 60.6 and values ranging from 5.9–11,324. Low anti-SeV antibodies background does not block the ability of SeV-base vaccine to promote antigen-specific T cell immunity.
Once common on the east coast of Australia, emus are now uncommon there; by contrast, the development of agriculture and the provision of water for stock in the interior of the continent have increased the range of the emu in arid regions. Emus live in various habitats across Australia both inland and near the coast. They are most common in areas of savannah woodland and sclerophyll forest, and least common in heavily populated districts and arid areas with annual precipitation of less than 600 millimetres (24 in). Emus predominantly travel in pairs, and while they can form large flocks, this is an atypical social behaviour that arises from the common need to move towards a new food source. Emus have been shown to travel long distances to reach abundant feeding areas. In Western Australia, emu movements follow a distinct seasonal pattern – north in summer and south in winter. On the east coast their wanderings seem to be more random and do not appear to follow a set pattern.
Sources: en.wikipedia.org
Historically, the birth rate of teenagers peaked in the late 1950s and early 1960s. However, at that time, most teenage parents were married. In the early twenty-first century, nine in ten births to the age group 15-19 are to unmarried mothers. Social norms have changed; it is now not unusual for teenagers to delay or avoid sexual intercourse altogether. Younger teenagers are more likely to practice abstinence than their older counterparts. A report published by the Center for Disease Control and Prevention (CDC) in early 2018 found the number of high school students who have had sex fell from 47% in 2005 down to 41% in 2015, with the most dramatic drop taking place between 2013 and 2015. On top of that, among never-married teens who have had sex, overwhelming majorities reported they used contraception the first time they did it. There are a few reasons for this. First, Millennials and Generation Z are more focused on the consequences of sex than their predecessors were. Second, there has been growing concern over unwanted sexual advances, especially in the wake of the Me-too movement. Writing for The Spectator, Douglas Murray dubbed this the "sexual counter-revolution." Third, as a consequence of the precarious contemporary economy, young adults today are more likely to be living with their parents rather than on their own, with a romantic partner, or a spouse. A 2016 analysis by the CDC discovered that teenage birthrates nosedived between 1991, when they reached a crisis point, and 2014, when they dropped by 60%, a record low.
In some countries, the black soldier fly, Hermetia illucens, is used to process food industry by-products and food waste. Hermetia illucens is a facultative necrophage and can grow on a wide range of decomposing organic substrates including those of animal origin (e.g. abattoir waste), plant origin (e.g. almond hulls), and a mix of both (e.g. meat, fish and vegetable food waste). Fly larvae are grown on this organic waste and then used as livestock feed or fish feed. The frass generated by the larvae can be used as soil fertilizer too. This waste conversion process, known as bioconversion, has several advantages. It reduces the greenhouse gas emissions caused by microbial decomposition of food waste in landfills (e.g. methane), it generates high-quality protein for feeding livestock, and it generates low-cost fertilizer for crop cultivation.
The Essential Programme on Immunization (EPI) is a global health initiative led by the World Health Organization agency. It aims to make vaccines available to all globally. It was launched in May 1974 under the old name of Expanded Programme on Immunization. Vaccination has been one of the most impactful public health interventions of the past century. Vaccines have provided the single greatest contribution to improving health outcomes globally, particularly among children and infants. Over its first 50 years, the EPI has prevented 154 million deaths, among which 146 million are in children younger than 5 years of whom 101 million are in infants younger than 1 year. Measles vaccination is the single greatest contributor of lives saved by vaccination, preventing 93.7 million deaths out of total 154 million deaths prevented by vaccination globally. The vaccination has contributed for 40% of the decline in global infant mortality, 52% in the African region. In 2024, a child younger than 10 years is 40% more likely to survive to their next birthday relative to a hypothetical scenario of no vaccination. Increased survival probability is observed into adulthood as well, individuals aged 25 years are 35% more likely, and those aged 50 years are 16% more likely to survive to their next birthday. When the EPI was founded, it focused on childhood vaccination to protect the youngest and most vulnerable.
Adjuvants may make vaccines too reactogenic, which often leads to fever. This is often an expected outcome upon vaccination and is usually controlled by oral paracetamol if necessary. Some more severe adverse effects that may exist are: Aluminium salts used in many human vaccines are regarded as safe by Food and Drug Administration. Aluminum has been suspected to play a role in the development of Alzheimer's disease (AD) ever since 1910 (the modern hypothesis dates to 1965); if there is a link between Al and AD, some concern about intentionally injecting aluminum would be reasonable. However, this "aluminum hypothesis" is not accepted by mainstream AD researchers: the evidence for aluminum having such an effect is scarce and weak compared to the evidence against such an idea. This theory is treated with great disinterest in the mainstream as there's no point in testing something that has failed almost every test. The aluminum hypothesis is one of the medical theories that has wider public acceptance than among professions. About one in 100,000 French people who receive aluminum adjuvants are diagnosed with macrophagic myofasciitis (MMF). When treated as a medical condition, MMF has symptoms such as muscle pain and fever. Many people who have these symptoms have the "MMF lesion", where an aluminum deposit seems to be causing a perpetual cycle of macrophages ingesting Al and dying from it, though it remains debated whether the two things have a link. It can be treated by a surgery that removes the deposit.
Disrupting the drug release mechanism. Prolonging gastric emptying. Changing the amount of gastric acid. Enhancing the drug absorption due to an increase in solubility. Increasing the wetting effect and therefore speeding up the drug release. A decrease in swelling capacity by the matrix, accelerating the release.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.